| Target Price | $76.50 |
| Price | $93.22 |
| Deviation |
17.94%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target iRadimed Corp 2026 .
The average iRadimed Corp target price is $76.50.
This is
17.94%
register free of charge
$78.75
15.52%
register free of charge
$75.75
18.74%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend iRadimed Corp to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the iRadimed Corp stock has an average upside potential 2026 of
17.94%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 73.24 | 82.71 |
| 11.71% | 12.93% | |
| Net Margin | 26.26% | 28.55% |
| 0.14% | 8.74% |
4 Analysts have issued a sales forecast iRadimed Corp 2025 . The average iRadimed Corp sales estimate is
This results in the following potential growth metrics:
4 iRadimed Corp Analysts have issued a net profit forecast 2025. The average iRadimed Corp net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.50 | 1.86 |
| 11.11% | 24.00% | |
| P/E | 50.22 | |
| EV/Sales | 13.65 |
4 Analysts have issued a iRadimed Corp forecast for earnings per share. The average iRadimed Corp EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Roth MKM |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Roth MKM:
Locked
➜
Locked
|
Feb 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


